Another example of the importance of the CTS is an acquired mutation (P168A) in Bax that confers resistance of acute myeloid leukemia (AML) cells to the FDA approved Bcl-2 inhibitor, Venetoclax [56]. This evidence concerns the gene BCL2 and acute myeloid leukemia.